SCHEMBL4253897

SCHEMBL4253897

Cc1cccc(NC(=O)c2cccc(C)c2)c1

nearest known ligand 0.93

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 12/20 0.93
KCNK9 Q9NPC2 8/20 0.93
MEN1 O00255 5/20 0.93
KMT2A Q03164 5/20 0.93
KCNH2 Q12809 1/20 0.93
RXFP1 Q9HBX9 1/20 0.93
POLB P06746 1/20 0.84
RAB9A P51151 3/20 0.73
NPC1 O15118 2/20 0.73
TP53 P04637 1/20 0.73
HTT P42858 1/20 0.72
L3MBTL1 Q9Y468 1/20 0.71
THRB P10828 1/20 0.71
NT5E P21589 1/20 0.71
CYP1A2 P05177 1/20 0.70
CYP3A4 P08684 1/20 0.70
GAA P10253 1/20 0.70
MAPT P10636 1/20 0.70
CYP2C9 P11712 1/20 0.70
CYP2C19 P33261 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16681527 0.93 KCNK3 (0.87) KCNK3KCNK9MEN1KMT2AKCNH2
SCHEMBL21377679 0.91 KCNK3 (0.84) KCNK3KCNK9MEN1KMT2AKCNH2
SCHEMBL30608967 0.91 KCNK3 (0.87) KCNK3KCNK9MEN1KMT2AKCNH2
SCHEMBL259666 0.91 KCNK3 (0.87) KCNK3KCNK9MEN1KMT2AKCNH2
SCHEMBL259468 0.91 KCNK3 (0.87) KCNK3KCNK9MEN1KMT2AKCNH2
SCHEMBL29434800 0.91 KCNK3 (0.87) KCNK3KCNK9MEN1KMT2AKCNH2
SCHEMBL16675166 0.91 KCNK3 (0.89) KCNK3KCNK9MEN1KMT2AKCNH2
SCHEMBL2908619 0.91 MEN1 (0.89) KCNK3KCNK9MEN1KMT2AKCNH2
SCHEMBL11669212 0.90 KCNK3 (0.81) KCNK3KCNK9MEN1KMT2AKCNH2
SCHEMBL10806300 0.90 MEN1 (0.81) KCNK3KCNK9MEN1KMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118420484-B Method for preparing amide compounds 四川大学 2024-08-30 CN disclosed
CN-118420484-A Method for preparing amide compounds 四川大学 2024-08-02 CN disclosed
EP-3312160-A1 HEPATITIS B ANTIVIRAL AGENTS Novira Therapeutics Inc. (US) 2018-04-25 EP disclosed
EP-1773786-B1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-04-26 EP disclosed
US-20160082699-A1 RESIN LAYER-ATTACHED SUPPORTING SUBSTRATE AND METHOD FOR PRODUCING SAME, GLASS LAMINATE AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING ELECTRONIC DEVICE ASAHI GLASS COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-20160075110-A1 FLEXIBLE SUBSTRATE AND METHOD FOR PRODUCING SAME, GLASS LAMINATE AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING ELECTRONIC DEVICE ASAHI GLASS COMPANY, LIMITED (JP) 2016-03-17 US disclosed
US-8357210-B2 Disazo acid dyes CLARIANT FINANCE (BVI) LIMITED (VG) 2013-01-22 US disclosed
EP-2027213-B1 DISAZO ACID DYES CLARIANT FINANCE BVI LTD (VG) 2012-11-21 EP disclosed
US-20110203058-A1 Disazo Acid Dyes CLARIANT FINANCE (BVI) LIMITED (VG) 2011-08-25 US disclosed
US-7754196-B2 Cosmetic composition comprising fiber L'OREAL (FR) 2010-07-13 US disclosed
US-20090126128-A1 Disazo Acid Dyes CLARIANT FINANCE (BVI) LIMITED (VG) 2009-05-21 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
WO-2009016088-A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
US-20080008932-A1 NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 2008-01-10 US disclosed
US-20080008932-A1 NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 2008-01-10 US disclosed
US-7157548-B2 Crosslinked sulfonated polyimide films HANYANG HAK WON CO., LTD. (KR) 2007-01-02 US disclosed
US-7157548-B2 Crosslinked sulfonated polyimide films HANYANG HAK WON CO., LTD. (KR) 2007-01-02 US disclosed
US-3988364-A ANTITUSSIVE AGENTS TOYO JOZO KABUSHIKI KAISHA (JA) 1976-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS GABBR1, GABBR2, CHRM2 KCNK3 1019/4885KCNK9 1229/4885MEN1 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.